Low expression of human leukocyte antigen (HLA) class I in human tumors may be related to defects of the antigenprocessing machinery (APM) components. Neuroblastoma cells are virtually HLA class I negative, but (i) the underlying mechanisms are unknown, and (ii) expression of the APM components has never been investigated. Here we have used a panel of novel monoclonal antibodies to proteasomal and immunoproteasomal components, chaperons and transporter associated with antigen processing (TAP) to characterize 24 stroma-poor neuroblastoma tumors and six neuroblastoma cell lines. Primary tumors showed defects in the expression of zeta, tapasin, TAP1 or TAP2, HLA class I heavy chain and b2 microglobulin, LMP2 and LMP7, as compared to normal adrenal medulla. Neuroblastoma cell lines displayed roughly similar patterns of APM expression in comparison to primary tumors. Incubation of neuroblastoma cell lines with interferon-c caused upregulation of HLA class I molecules and reduced lysis by killer inhibitory receptor HLA ligand-matched NK cells. Defects in APM components explain reduced peptide loading on HLA class I molecules, their instability and failure to be expressed on the cell surface. HLA class I upregulation by interferon-c, although enhancing neuroblastoma cell recognition by cytotoxic T cells, dampens their susceptibility to NK cells.
Introduction
Neuroblastoma (NB) derives from the neural crest and affects mostly children below the age of 10 years (Brodeur, 2003) . Novel therapies are needed for this tumor, since more than 50% of patients suffer from metastatic disease at diagnosis, and only 25-30% of them survive at 5 years, in spite of high-dose chemotherapy and hematopoietic rescue with autologous stem cell transplantation (Brodeur, 2003) .
The limited efficacy of chemotherapy and radiotherapy in the treatment of different tumor types has fostered the development and application of alternative therapeutic strategies. Among them, immunotherapy has attracted much interest because of the identification of a wide number of tumor-associated antigens, and of the availability of novel molecules able to target malignant lesions. T-cell-based immunotherapy has been emphasized because of the general belief that T cells have a major role in the control of tumor growth. The role played by human leukocyte antigen (HLA) class I antigens in the interactions of target cells with cytotoxic T lymphocytes (CTL) (Zinkernagel and Doherty, 1974) has rekindled interest in the characterization of the mechanism(s) underlying defects in HLA class I antigen expression and/or function, which are frequently present in malignant cells (Garrido et al., 1997) . On the other hand, such defects render tumor cells more susceptible to lysis operated by NK cells, which can be administered for therapeutic purposes. Thus, new information on the nature of HLA defects in tumor cells may allow a more accurate selection of patients candidate to receive cellular immunotherapy and eventually improve their outcome.
It has been known for some time that HLA class I antigen expression is virtually undetectable in NB cells (Lampson and George, 1986; Wolfl et al., 2005) , but can be upregulated by incubating NB cell lines with recombinant interferon (rIFN)-g (Lampson and George, 1986) . This phenotype is compatible with defects in the antigen-processing machinery (APM) (Seliger et al., 2002) .
In most tumors, abnormalities in the APM reflect dysfunctional and nonstructural mechanisms (Seliger et al., 2000) . They may cause defects in peptide generation, translocation and/or loading onto b 2 microglobulin (m)-HLA class I heavy chain (HC) complexes (Seliger et al., 2000) . As a consequence, these complexes are retained in the endoplasmic reticulum, are degraded by housekeeping proteasomes to a larger extent and are unstable. IFN-g treatment usually restores peptide supply to b 2 m-HC complexes by upregulating APM component expression (Seliger et al., 2000) , and reverses HLA class I antigen downregulation.
Another modification of the APM components caused physiologically by IFN-g is the replacement of the housekeeping proteasomal subunits delta, MB-1 and zeta with the low-molecular-weight protein immunoproteasomal subunits (LMP)2, LMP7 and LMP10, respectively, leading to improved generation of immunogenic peptides (Tanaka and Kasahara, 1998) .
To the best of our knowledge, scanty information is available about the mechanisms underlying HLA class I downregulation in NB cells. Only a limited number of NB cell lines, but not primary tumors, have been analysed so far for the expression of transporter associated with antigen processing (TAP)1 mRNA and protein, and of TAP2 and tapasin mRNA (Corrias et al., 2001) .
In the present study, utilizing a panel of newly developed mAbs, we have performed for the first time a systematic analysis of the expression of APM components in NB lesions and cell lines. The information obtained provides an explanation for the failure of NB cells to express HLA class I molecules and represents a rationale background for the design of CTL-or NK cell-based immunotherapeutic strategies.
Results

APM component expression in primary NB lesions
Formalin-fixed, paraffin-embedded tissue sections from 24 newly diagnosed primary NB, Schwannian stroma poor, tumors were stained in the immunoperoxidase reaction with APM component-specific mAb. Expression of the zeta proteasomal subunit and TAP2 subunit could be investigated only in 14 formalin-fixed, paraffinembedded tumors, since 10 lesions were not available for this study.
With each tumor sample, microscopic areas enriched for neuroblasts were selected for visual assessment of mAb staining and semiquantitative evaluation of positive cells. To this end, serial tissue sections of each tumor were stained with CD45 and NB84 mAb to distinguish cells of hematopoietic origin from neuroblasts, and subsequently with APM component-specific mAb. A representative tissue staining with NB84 or CD45 mAb is shown in Figure 1Aa and b, respectively. Microscopic areas containing at least 80-90% NB84-positive, CD45-negative neuroblasts were examined. Figure 1B shows representative stainings obtained with mAb recognizing MB-1 (panel a), delta (panel b) and zeta (panel c) housekeeping proteasomal subunits, LMP2 (panel d) and LMP10 (panel e) immunoproteasomal components, and calnexin (panel f), calreticulin (panel g) and ERp-57 (panel h) chaperons. Table 1 shows the percentage of positive neuroblasts stained by the APM component-specific mAb in the NB tumors analysed.
The staining intensity of the majority of tumor cells in every lesion was strong for MB-1, delta and LMP10.
The staining intensity for zeta and LMP2 ranged from faint to strong. The latter components were detected in 50 and 30%, respectively, of the lesions analysed (Table 1) . The staining pattern for calnexin, calreticulin and ERp-57 ranged from faint to strong. These molecules were expressed in a percentage ranging from 80 to 100% of the lesions analysed (Table 1) .
LMP7, tapasin, TAP2, b 2 m, b 2 m-free HC and HLA class I and II antigens were not detected in any of the lesions analysed (Table 1) .
Tumor-infiltrating lymphoid cells served as a positive internal control, since they were stained by all the mAbs tested, including the seven that did not react with NB cells. Figure 1C þ , NB84 À cells of hematopoietic origin were selected as detailed above (see Figure 1A) .
In a separate set of experiments, frozen tissue sections from primary NB tumors were stained with the anti-TAP1 mAb, since this mAb does not stain formalinfixed, paraffin-embedded tissue sections. Such analysis was limited to eight tumors, since frozen samples from the remaining 17 tumors were not available. No staining of neuroblasts was detected. In contrast, infiltrating lymphoid cells were consistently stained by anti-TAP1 mAb (not shown).
No correlation was found between defect in the expression of individual APM components and tumor cell ploidy, genetic abnormalities (MYCN amplification, chromosome 1p deletion), prognostic category or clinical presentation at onset, that is, localized vs metastatic (Table 1) .
APM component expression in adrenal medulla
To define the APM component expression profile in a normal counterpart of NB tumors, the medulla from a pediatric adrenal gland was stained with APM component-specific mAb in the immunoperoxidase reaction. Figure 2 shows the staining patterns obtained with mAb recognizing delta, zeta and MB-1 housekeeping proteasomal subunits, LMP2, LMP7 and LMP10 immunoproteasomal components, the calnexin, calreticulin and tapasin chaperons, TAP2 subunit, ERp-57 thiol-reductase, b 2 m-free HC and b 2 m. TAP1 staining was not performed due to the lack of frozen tissue sections. The staining intensity of most adrenal medulla cells was strong for delta These results demonstrate that absence of tapasin, TAP2, b 2 m-free HC and b 2 m in primary NB lesions is related to malignant transformation.
Expression and modulation by rIFN-g of APM components in human NB cell lines Expression of APM components was next investigated in the human NB cell lines ACN, GI-ME-N, HTLA-230, IMR-32, LAN-5 and SHSY5Y, which display different characteristics. While the cell lines HTLA-230, IMR-32 and LAN-5 are MYCN amplified, the remaining three are not (Thiele, 1999) . Furthermore, only ACN and SHSY5Y express constitutively HLA-A, B and C antigens on their surface membrane (Corrias et al., 2001) .
Previously, it was shown that rIFNg upregulates HLA-A, B and C antigen expression on the surface of 
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The prognostic category (PC) has been evaluated according to the International Neuroblastoma Pathology Classification. (Lampson and George, 1986) . In this study, APM component expression was evaluated in the six cell lines under basal conditions and following 48 h incubation with human rIFN-g (1000 U/ml). Table 2 shows expression under basal conditions of APM components in all cell lines, as assessed by a semiquantitative mean relative fluorescence intensity (MRFI) score. As apparent, defective expression of different components was detected in the cell lines regardless of the HLA class I-positive or -negative phenotype. Antigen-processing machinery in neuroblastoma L Raffaghello et al Figure 3 shows the means7standard error (s.e.) of the MRFI obtained by staining the six NB cell lines with mAb. The left panel of Figure 3a shows the results with a basal MRFI lower than 2, while the left panel of Figure 3b shows those with a basal MRFI higher than 2. In both panels, expression of the APM components in the Raji Burkitt's lymphoma cell lines under baseline conditions is shown for comparison.
MB-1, LMP2, LMP7, LMP10, TAP1, ERp-57 and tapasin expression was low to virtually undetectable in NB cell lines under basal conditions; however, LMP2 and tapasin levels were significantly upregulated (P ¼ 0.02) in NB cell lines incubated with rIFN-g ( Figure 3a , left panel). A representative experiment of upregulation is shown in the inset of Figure 3a , left panel.
Delta, zeta, calnexin and calreticulin were the APM components expressed at the highest levels in NB cell lines under basal conditions; such levels were not significantly increased following incubation with rIFN-g (Figure 3b , left panel). Antigen-processing machinery in neuroblastoma L Raffaghello et al Finally, intracellular b 2 m-free HC, b 2 m and HLA-A, B and C molecules were expressed in NB cell lines at low to moderate levels and they were significantly upregulated upon incubation with rIFN-g (P ¼ 0.02) (Figure 3b, left panel) . A representative experiment is shown in the inset of Figure 3b , left panel.
When expression of the APM components was analysed separately in HLA class I-positive and -negative cell lines (Figure 3a and b, right panels) , the overall patterns detected under baseline conditions and following incubation with rIFN-g were similar.
Expression of APM components was not significantly different in MYCN-amplified and nonamplified NB cell lines (Figure 3a and b) .
Upon incubation with rIFN-g, HLA-A, B and C antigen expression was induced de novo on the surface of the GI-ME-N, HTLA-230, IMR-32 and LAN-5 cell lines (Table 3) . ACN and SHSY5Y cells displayed upregulation of surface HLA class I antigens (Table 3) . rIFN-g induced HLA class II antigen expression only on ACN cells (not shown).
Surface staining for b 2 m showed that its expression was low to absent in all cell lines but ACN and SHSY5Y, and strongly upregulated in most of them by rIFN-g stimulation; such phenomenon was of a lower order of magnitude in GI-ME-N cells (Table 3) . Surface expression of b 2 m-free HC was low to absent under basal conditions in all cell lines but SHSY5Y, and was upregulated in ACN and LAN-5 cells following incubation with rIFN-g ( Table 3 ).
Induction of surface HLA class I expression in NB cells by rIFN-g decreases their susceptibility to NK cell-mediated lysis In order to address the functional impact of surface HLA-A, B and C induction in NB cells by rIFN-g with regard to NK-mediated cytolytic activity, we performed cytotoxic assays using IL-2-activated NK cell populations from different healthy donors as effectors and IMR-32, GI-ME-N, HTLA-230 or LAN-5 NB cells, which had been untreated or treated with rIFN-g for 48 h, as targets. In the representative experiment shown in Figure 4a , HLA-A, B and C upregulation in IMR-32 cells by IFN-g occurred in the virtual absence of intracellular TAP1 upregulation (see also Figure 3a) .
Lysis of IFN-g-treated HLA class I-negative NB cell lines (GI-ME-N, HTLA-230, IMR-32 and LAN-5) by NK cells from healthy donors matched for HLA class I ligands of killer inhibitory receptors (KIR) (Moretta et al., 1996; Ruggeri et al., 2002) was significantly reduced at the 50 : 1 and 25 : 1 E/T ratios (Po0.01 and 0.02, respectively). One representative experiment performed with the IMR-32 cell line is shown in Figure 4b .
In contrast, no reduction of lysis of the same rIFN-gtreated cell lines was detected when they were incubated with activated NK cells from healthy donors mismatched for KIR HLA class I ligands (not shown).
These experiments demonstrate that IFN-g-mediated upregulation of surface HLA class I molecules on NB cells impairs their susceptibility to NK cell lysis.
Discussion
HLA class I antigens are virtually undetectable in most NB cell lines and can be upregulated by IFN-g (Lampson et al., 1983; Lampson and Fisher, 1984; Ponzoni et al., 1993; Brodeur, 2003) . This phenotype suggests that functional abnormalities in the APM account for defective HLA class I antigen expression in NB cells (Lampson and George, 1986) . To the best of our knowledge, this issue has never been addressed in previous investigations.
The present results show for the first time that multiple APM components are downregulated or undetectable in both primary NB lesions and in NB cell lines, based upon the comparative expression in the adrenal medulla. This tissue was selected as normal counterpart since (i) it shares with NB the same neuroectodermal origin, (ii) the majority of NB tumors present with adrenal gland involvement at diagnosis; and (iii) MYCN transgenic mice develop spontaneous NB always involving the adrenal medulla (Weiss et al., 1997) .
The housekeeping proteasomal subunits delta and MB-1 were detected in most NB lesions, whereas Antigen-processing machinery in neuroblastoma L Raffaghello et al the zeta subunit was expressed in half of the samples tested. These findings suggest that a subset of primary NB tumors have impaired catalytic activity of the housekeeping proteasome due to downregulation of zeta. Incubation of normal cells with IFN-g causes the replacement of the housekeeping proteasomal subunits with the inducible LMP2, LMP7 and LMP10 immunoproteasomal components (Groettrup et al., 1996; Hochstrasser, 1996; Tanaka and Kasahara, 1998) . All of the latter molecules were detected in the control adrenal medulla, likely in relation to the availability of inflammatory cytokines due to chronic pyelonephritis. Primary NB tumors were found to express LMP10 in all samples, LMP2 in half of them and LMP7 in none. Immunoproteasomal component expression in tumor cells may be consequent to IFN-g secretion by infiltrating lymphocytes (Facchetti et al., 1996) . However, susceptibility to induction by IFN-g may be different for each subunit.
Calnexin, calreticulin and ERp-57 were detected in NB lesions, whereas TAP1, TAP2 or tapasin were not. In contrast, all of these APM components were expressed in the control adrenal medulla.
The impairment in peptide translocation from the cytosol to the endoplasmic reticulum and in loading of peptides onto HLA-A, B and C antigens resulting from TAP and tapasin downregulation in tumor cells (Seliger et al., 2000) , together with the defects in the assembly of HLA-A, B and C subunits (Garrido et al., 1997; Seliger et al., 2002) , is likely responsible for the lack of intracellular and surface HLA-A, B and C antigen expression observed in NB lesions (Williams et al., 2002; Zarling et al., 2003; Wolfl et al., 2005) .
The overall pattern of staining of the six NB cell lines with APM-specific mAb generally resembled that found in primary tumors. Notable exceptions were LMP10 expression in NB lesions, which could not be detected in any cell line, and the presence of b 2 m, b 2 mfree HC and HLA-A, B and C molecules in the cytoplasm of NB cell lines, but not of primary tumor cells. These differences may be related to the selection of tumor subclones during the establishment of NB cell lines and/or to changes in the antigenic profile caused by long-term culture. Alternatively, the different sensitivity of the techniques used to analyse surgically removed tumors and cell lines, that is, immunohistochemical staining and flow cytometry, may account for these discrepancies.
When NB cell lines were incubated with rIFN-g, upregulation of intracellular LMP2, tapasin, b 2 m-free HC, b 2 m and HLA-A, B and C antigens, as well as of surface HLA-A, B and C molecules, was observed. Furthermore, rIFN-g treatment induced surface b 2 m upregulation in all cell lines (Marozzi et al., 1993) and surface b 2 m-free HC upregulation in two of them (Pickl et al., 1993) . A possible explanation for these findings is that b 2 m and HC dissociate from some HLA-A, B and C complexes that do not contain peptides and are therefore unstable.
The functional impact of IFN-g-induced, TAP-independent HLA-A, B and C upregulation was demonstrated by the decreased killing of rIFN-g-treated NB cell lines by activated NK cells from normal donors matched for KIR HLA class I ligands. In this connection, NXS2 murine NB cells have been reported to express increased levels of major histocompatibility complex (MHC) class I antigens upon recurrence following NK cell-dependent immunotherapy (Neal et al., 2004) . Thus, NB tumor cells may acquire resistance to NK cell-mediated lysis and escape from the control of the immune system (Neal et al., 2004) .
On the other hand, IFN-g-transfected murine NB tumors are rejected by the host immune system through Antigen-processing machinery in neuroblastoma L Raffaghello et al CTL-dependent mechanisms (Watanabe et al., 1989) , and growth of IFN-g-transfected human NB cells in nude mice is delayed (Airoldi et al., 2004) . Furthermore, IFN-g-or retinoid-treated human NB cell lines can present immunogenic peptides to CTL in an HLArestricted manner and be lysed in vitro by the latter effectors (Sarkar and Nuchtern, 2000; Passoni et al., 2002; Vertuani et al., 2003) .
Therefore, pharmacological manipulation of NB cells aimed at upregulating surface HLA class I expression can favor CTL-mediated killing but dampen lysis operated by NK cells. In order to design efficacious immunotherapy protocols against NB, this 'doubleedged sword' must be finely tuned to increase the overall level of tumor cell recognition by the host immune system.
In conclusion, this study demonstrates that human NB shows multiple defects in the expression of the APM components, and that these defects are nonstructural in nature, but rather reflect abnormalities in regulatory mechanisms involved in the expression of these molecules (Seliger et al., 2000) . The present results provide relevant background information for future immunotherapeutic approaches to NB treatment.
Materials and methods
Patients
The main characteristics of the patients from whom the lesions analysed in this study were obtained are summarized in Table 1 . Three patients with stage 4 disease had tumors with amplification of the MYCN oncogene (Tonini et al., 1997) . Six patients had chromosome 1p deletion (Pinkel et al., 1986) ; three of them had also MYCN amplification. The ploidy status of tumor cells was evaluated by flow cytometry (Hedley et al., 1985) . Of the 22 patients tested, three had diploid and 19 aneuploid tumor cells. The prognostic category of patients was defined as favorable or unfavorable according to the International Neuroblastoma Pathology Classification (INPC) criteria (Shimada et al., 1999b) .
The criteria utilized for diagnosis and evaluation of disease extension were reported elsewhere (Brodeur et al., 1988) . Briefly, diagnosis was based on histological grounds or on bone marrow infiltration by tumor cells, usually associated with elevated urinary catecholamine excretion. The disease was staged according to the criteria of the International Neuroblastoma Staging System (INSS) (Brodeur et al., 1988) . They include the measurement of primary tumor size determined by ultrasonography and/or computed tomography, bone marrow infiltration assessed by at least one aspirate, skeletal involvement determined by plain X-ray survey and/or technetium 99 m DPM scintigraphy, and the level of urinary vanillylmandelic and homovanillic acids, and of serum lactate dehydrogenase (Brodeur et al., 1988) .
Tissues and cell lines
The primary neuroblastic tumors used in this study were obtained from patients at diagnosis, before the implementation of any therapy. Only NB, Schwannian stroma poor, tumors were investigated (Shimada et al., 1999a) , since stromal cells present in lesions may interfere in the analysis of APM component expression in malignant neuroblasts. Tonsils were obtained from patients undergoing tonsillectomy for inflammatory disorders; tonsil tissue sections were preliminarily used to optimize mAb amounts for immunohistochemical staining. An adrenal gland was surgically removed from a pediatric patient with kidney cystic dysplasia complicated by pyelonephritis. The adrenal medulla was used to assess the APM component expression in a normal counterpart of human NB. Tissue samples were fixed in 20% buffered formalin, routinely processed and embedded in paraffin. One part of some of the lesions was snap-frozen in liquid nitrogen and stored at À801C.
The ACN, GI-ME-N, HTLA-230, IMR-32, LAN-5 and SHSY5Y NB cell lines, and the Raji Burkitt's lymphoma cell line were cultured in RPMI 1640 medium (Sigma, St Louis, MO, USA) supplemented with L-glutamine, penicillin/streptomycin, nonessential amino acids and 10% fetal bovine serum (FBS, Sigma). The Raji Burkitt's lymphoma cell line was tested as positive control in flow cytometry experiments with all mAbs (see below). Cell lines were incubated for 48 h with human rIFN-g (Imuchin s , Boehringher Ingelheim Italia, Florence, Italy) at the final concentration of 1000 IU/ml, which in preliminary titration experiments proved to be optimal for HLA-A, B and C upregulation on NB cell lines.
Monoclonal and polyclonal antibodies
The mAb HC-10, which recognizes a determinant expressed on all b 2 m-free HLA-B HC and on b 2 m-free HLA-A10, -A28, -A29, -A30, -A31, -A32 and -A33 HC (Stam et al., 1986; Puppo et al., 1999) ; the anti-b 2 m mAb L368 (Lampson et al., 1983) ; the mAb TP25.99, which recognizes a conformational determinant expressed on all b 2 m-associated HLA-A, B and C HC and a linear determinant expressed on all b 2 m-free HLA-B HC except HLA-B73, and on b 2 m-free HLA-A1, -A3, -A9, -A11 and -A30 HC (Desai et al., 2000) , and the anti-HLA-DR, DQ and DP mAb LGII-612.14 (Temponi et al., 1993) were developed and characterized as described (Temponi et al., 1993) . The anti-MB-1 mAb SJJ-3, the anti-delta mAb SY-4, the anti-zeta mAb NB1, the anti-LMP2 mAb SY-1, the anti-LMP7 mAb SY-3, the anti-LMP10 mAb TO-7, the anti-TAP1 mAb TO-1, the anti-TAP2 mAb SY-2, the anti-calnexin mAb TO-5, the anti-ERp-57 mAb TO-2, the anti-calreticulin mAb TO-11 and the anti-tapasin mAb TO-3 were developed and characterized utilizing methodology described elsewhere (Kishore et al., 1998; Ogino et al., 2003b) . With the exception of mAb HC-10, which is an immunoglobulin (Ig)G2a, all the other mAbs are of the IgG1 isotype. Isotype-and subclassmatched mouse Ig (Southern Biotechnology Associates, Birmingham, AL, USA) were used as negative controls. The NB-specific mAb NB84 and the mAb CD45R0, which detects cells of hematopoietic origin, were purchased from Dako, Glostrup, Denmark.
FITC-conjugated F(ab 0 ) 2 fragments of rabbit anti-mouse IgG antibodies were purchased from Dako.
Immunohistochemical staining of tissues
Immunohistochemical staining of tissue sections was performed using the Envision System HRP mouse (Dako). Briefly, 5 mm thick sections were cut from formalin-fixed, paraffin-embedded blocks, deparaffinized with xylene and rehydrated by passages through decreasing concentrations of ethanol (from 100 to 80% Frozen tissue sections were used as substrate for immunohistochemical staining with anti-TAP1 mAb TO-1, the only mAb that does not stain formalin-fixed, paraffin-embedded tissue sections. To this end, frozen tissue sections were cut, fixed in ice-cold acetone for 10 min at room temperature, dried and washed twice with Optimaxt Wash Buffer. Endogenous peroxidase activity was blocked by a 30 min incubation at room temperature with methanol containing 3% H 2 O 2 . Tissue sections were washed twice with Optimaxt Wash Buffer and incubated overnight at 41C with an optimal amount of anti-TAP1 mAb TO-1 or with isotype-and subclassmatched mouse Ig. All the subsequent steps of the staining procedure were carried out as described for the procedure utilizing formalin-fixed, paraffin-embedded tissue sections as substrate. The percentage of stained tumor cells in each lesion was evaluated independently by two investigators. The variation between the results obtained by the two investigators was less than 10%. Results were scored as negative, heterogeneous and positive, when the percentage of stained tumor cells in each microscopic area was less than 25%, between 25 and 75% and more than 75%, respectively (Kageshita et al., 1999) . Areas containing at least 80-90% neuroblasts, as assessed by immunohistochemical staining of serial tissue sections with mAb NB84 and CD45, were selected at low magnification and then carefully analysed at higher magnification ( Â 63). The assignment of each tumor sample in one of the above scores was based upon the score of the microscopic area containing the highest percentage of mAb-positive neuroblasts.
The staining pattern was defined as faint or strong according to the individual microscopical evaluation of two independent investigators using the staining intensity of normal infiltrating lymphoid cells as standard.
Flow cytometric analysis of cell lines
The intracellular staining of cell lines with mAb was performed as described (Ogino et al., 2003a) . Briefly, cells were washed three times with phosphate-buffered saline (PBS, Sigma) containing 1% FBS (staining buffer) and fixed with 2% paraformaldehyde at room temperature for 20 min. Then, cells were washed three times with staining buffer, and resuspended at 5 Â 10 5 /ml of PBS containing 0.5% FBS for the microwave treatment at 200 W power for 45 s. Cells were chilled on ice for 10 min, washed twice with staining buffer and incubated in permeabilization buffer (PBS, 1% FBS, 0.1% saponin, Sigma) for 30 min at room temperature. Cells (5 Â 10 5 /tube) were incubated with the primary mAb for 30 min at room temperature, then washed twice with permeabilization buffer and incubated with FITC-conjugated F(ab 0 ) 2 fragments of rabbit anti-mouse IgG antibodies for 30 min at room temperature. Cells were then washed twice in permeabilization buffer and resuspended in staining buffer before being analysed by flow cytometry using a FACScan instrument (BD Biosciences, San Jose, CA, USA).
For surface staining, cells were sequentially incubated with an optimal amount of primary mAb and with an optimal amount of FITC-conjugated F(ab 0 ) 2 fragments of rabbit anti-mouse Ig antibodies. Stained cells were analysed by flow cytometry. Isotype-and subclass-matched mouse Ig were used as negative controls in all the experiments. Cell Quest software (BD Biosciences) was used for data analysis. The results of flow cytometry experiments are expressed as MRFI, that is, the ratio between the mean fluorescence intensity (MFI) of cells stained with the selected mAb and the MFI of cells stained with the isotype-matched mouse Ig.
Preparation and culture of NK-enriched cell suspensions
Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll-Hypaque density gradient centrifugation of heparinized normal blood samples. PBMC were washed and resuspended in RPMI 1640 complete medium and depleted of monocytes by adherence to plastic for 1 h at 371C. To enrich for NK cells, PBMC were depleted of T lymphocytes by rosetting with neuraminidase-treated sheep erythrocytes and subsequently incubated with CD14 (Dako) and anti-HLA-DR (D1.12, generously donated by Dr R Accolla) mAbs (30 min at 41C) followed by goat anti-mouse IgG antibody-coated magnetic beads (Immunotech, Marseille-France), according to the manufacturer's instructions. The resulting cell fractions contained consistently at least 90% CD3
þ NK cells, as assessed by double staining with CD3 and CD56 mAbs (BD Biosciences, San Jose, CA, USA). PBMC from normal donors and target cell lines were HLA typed using a molecular technique (Olerup and Zetterquist, 1992) . Enriched NK cell suspensions were cultured overnight at 371C in complete medium supplemented with 100 U/ml rIL-2 (Proleukin, Chiron Italia s.r.l., Milan, Italy).
Cytotoxicity assays
NK cells cultured overnight at 371C with rIL-2 were tested for cytotoxic activity in a 4 h 51 Cr-release assay as previously described (Facchetti et al., 1999) . Briefly, IMR-32 NB cells, untreated or treated with 1000 U/ml rIFN-g for 48 h, were labeled with Na 2 51 CrO 4 (Amersham, Buckingam-Shire, UK) for 1 h at 371C and washed three times. Labeled cells were then added to effector cells in V-bottom microwells at different effector to target ratios in a final volume of 200 ml. Results are expressed as percent specific lysis.
Statistical analysis
Results were compared using the unpaired t-test.
